New resource available view now
New resource available view now
Recent Post
Related Posts
IGC Pharma Advances Caregiver Engagement as Phase 2 CALMA Trial Advances Final Enrollment Phase
Outreach initiative supports awareness of agitation and patient engagement as enrollment approaches completion
Behavioral neurology expertise and expanded patient access support final phase of recruitment in Alzheimer’s agitation study
Authorization provides regulated capability to evaluate emerging therapeutic approaches alongside Phase 2 CALMA trial approaching completion
POTOMAC, Maryland – April 14, 2026 – IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”) today announced that it has approximately 80% patient enrollment in its Phase 2 CALMA clinical trial
POTOMAC, MARYLAND – April 08, 2026 – IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), a clinical-stage biotechnology company with its lead program currently in a Phase 2 CALMA clinical trial evaluating IGC-AD1 for Alzheimer’s-related agitation today announced that Ascendiant Capital Markets has